Brokerages expect Cambrex Co. (NYSE:CBM) to post $127.84 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Cambrex’s earnings, with the lowest sales estimate coming in at $122.04 million and the highest estimate coming in at $133.63 million. Cambrex reported sales of $112.62 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 13.5%. The business is scheduled to announce its next quarterly earnings report on Tuesday, November 6th.
According to Zacks, analysts expect that Cambrex will report full year sales of $568.72 million for the current year, with estimates ranging from $564.89 million to $572.55 million. For the next year, analysts anticipate that the business will post sales of $674.18 million, with estimates ranging from $663.91 million to $684.45 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Cambrex.
Cambrex (NYSE:CBM) last issued its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported $0.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.69 by $0.05. The company had revenue of $152.05 million for the quarter, compared to analyst estimates of $132.78 million. Cambrex had a net margin of 20.75% and a return on equity of 22.32%. Cambrex’s revenue was up 13.0% compared to the same quarter last year. During the same period last year, the company posted $0.76 earnings per share.
Several equities analysts recently issued reports on the stock. ValuEngine raised shares of Cambrex from a “sell” rating to a “hold” rating in a report on Friday, July 6th. Jefferies Financial Group initiated coverage on shares of Cambrex in a report on Tuesday, September 25th. They issued a “buy” rating and a $75.50 price target on the stock. Finally, Zacks Investment Research raised shares of Cambrex from a “hold” rating to a “strong-buy” rating and set a $73.00 price target on the stock in a report on Wednesday, August 8th. Two investment analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. Cambrex has a consensus rating of “Buy” and an average target price of $69.50.
CBM stock traded up $0.35 during trading on Monday, hitting $60.23. 266,603 shares of the company’s stock traded hands, compared to its average volume of 343,952. The firm has a market cap of $2.27 billion, a price-to-earnings ratio of 19.00, a PEG ratio of 2.43 and a beta of 2.44. Cambrex has a 1 year low of $42.55 and a 1 year high of $69.43.
In other Cambrex news, CEO Steven M. Klosk sold 55,000 shares of Cambrex stock in a transaction on Tuesday, September 4th. The shares were sold at an average price of $66.30, for a total value of $3,646,500.00. Following the transaction, the chief executive officer now directly owns 138,328 shares of the company’s stock, valued at $9,171,146.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Samantha Hanley sold 27,500 shares of Cambrex stock in a transaction on Monday, August 6th. The stock was sold at an average price of $62.64, for a total transaction of $1,722,600.00. Following the completion of the transaction, the vice president now directly owns 2,500 shares in the company, valued at $156,600. The disclosure for this sale can be found here. Insiders sold 278,760 shares of company stock worth $17,634,927 over the last ninety days. Corporate insiders own 2.42% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. raised its position in shares of Cambrex by 8.7% in the second quarter. BlackRock Inc. now owns 4,624,250 shares of the biotechnology company’s stock worth $241,849,000 after acquiring an additional 370,806 shares during the period. Bank of New York Mellon Corp raised its position in shares of Cambrex by 3.8% in the second quarter. Bank of New York Mellon Corp now owns 1,471,966 shares of the biotechnology company’s stock worth $76,982,000 after acquiring an additional 54,475 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Cambrex by 1.0% in the second quarter. Dimensional Fund Advisors LP now owns 1,420,580 shares of the biotechnology company’s stock worth $74,295,000 after acquiring an additional 13,858 shares during the period. American Capital Management Inc. raised its position in shares of Cambrex by 6.7% in the second quarter. American Capital Management Inc. now owns 720,476 shares of the biotechnology company’s stock worth $37,681,000 after acquiring an additional 45,312 shares during the period. Finally, Boston Partners raised its position in shares of Cambrex by 3.2% in the second quarter. Boston Partners now owns 699,286 shares of the biotechnology company’s stock worth $36,572,000 after acquiring an additional 21,399 shares during the period.
Cambrex Company Profile
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals.
Featured Story: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.